REGNRegeneron Pharmaceuticals
Is it safe?
Strong, no red flags: a safe balance sheet and comfortable debt (AA).
Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$3.3M, 90 days to Oct 8, 2026), selling is often routine.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Moderate price swings, typical volatility. Worst drawdown -60% · now 12% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can REGN take a bad year?
Regeneron Pharmaceuticals holds $6.01B more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- 6.47
Altman Z-score · safe zone, above 3
- Interest cover
- 69.4×
Interest cover · operating profit covers the interest bill several times over
Details›
- Total debtQ2 2026
- $1.99B
- Cash and short-term investments
- $7.99B
- Net cash
- $6.01B
- EBITDA, trailing twelve months
- $4.37B
- Operating profit, trailing twelve months
- $3.84B
- Debt / equity
- 0.06×
- Total debt / EBITDA
- 0.45×
- Annualised volatilitytwo years of daily moves
- 37%
- Worst drawdown on file
- −60%
- Below its 52-week high
- 12%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry